Pharma Mar | PHM - Cash And Equivalent


Pharma Mar reported EUR19.34M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
Avita Medical AUD 10.24M 1.98M Dec/2025
Dianthus Therapeutics USD 110.55M 517.12M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Moderna USD 1.72B 185M Jun/2026
Organon & Co USD 1.12B 542M Mar/2026
Pharma Mar EUR 19.34M 29.53M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026